Please assess the completion status of the following clinical trial:

Trial Title: A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with nerve pain after Spinal cord injury (traumatic, diving, ischemic and after removal of benign tumors (except meningioma and fibromas)~* Pain has to be chronic(continuous for at least 3 months or intermittent for at least 6 months~* Pain score at least 4 in 4 of 7 days prior to receive treatment.~Exclusion Criteria:~* Pregabalin use in the last 60 days, prior intolerance to pregabalin~* Creatinine clearance \<60 mL/min.~* White blood cell count \<2500/mm3; neutrophil count \<1500/mm3; platelet count \<100 x 103/ mm3.~* Abuse of drugs or alcohol~* Unstable medial conditions~* Clinically significant abnormal electrocardiogram (ECG).~* Presence of severe pain associated with conditions other than spinal cord injury that could confound the assessment or self-evaluation of pain due to spinal cord injury.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- matched placebo (Type: PLACEBO_COMPARATOR): None
- pregabalin (Type: EXPERIMENTAL): flexible dosing over 4 weeks followed by 12 weeks maintenance and one week taper period

Based on this trial design, predict the completion outcome and termination type (if applicable).